|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 4,906,463
Summary
U.S. Patent 4,906,463, granted on March 6, 1990, pertains to a specific chemical compound, its pharmaceutical formulation, and therapeutic uses. This patent, assigned to Novo Nordisk A/S, covers a class of somatostatin analogs that have potential applications in hormonal regulation, especially in treating hormone-secreting tumors. This analysis provides an in-depth review of its scope, claims, validity, and the intellectual property landscape surrounding this patent, facilitating strategic decisions in drug development and patent management within the pharmaceutical sector.
What Is the Scope of U.S. Patent 4,906,463?
Core Invention
The patent discloses a class of peptide analogs of somatostatin, characterized by specific amino acid sequences, which are optimized for increased stability and receptor affinity. These analogs are designed to have enhanced pharmacological profiles suitable for therapeutic use.
Main Focus
- Chemical Composition: Peptides based on modified amino acid sequences of native somatostatin.
- Therapeutic Application: Treatment of hormonal disorders such as acromegaly, carcinoid tumors, or other hormone-secreting neoplasms.
- Pharmaceutical Formulation: Methods of preparing and administering these peptides for effective therapy.
Claims Overview
The patent claims can be segmented into several categories:
- Peptide Structures: Specific amino acid sequences with defined modifications.
- Pharmaceutical Compositions: Methods of producing stable formulations.
- Therapeutic Use: Methods for treating particular hormonal disorders.
- Biological Activity: Demonstrations of receptor binding affinity and stability benefits.
Note: The patent emphasizes peptides with substitutions at particular positions to increase resistance to enzymatic degradation, prolonged half-life, and receptor specificity.
Analysis of the Patent Claims
Claim Scope Analysis
| Claim Number |
Type |
Content Summary |
Rationale |
Impact on Patent Scope |
| 1 |
Composition (Peptide) |
Defines a specific peptide sequence with amino acid substitutions, e.g., at positions 1, 3, or 8 |
Provides broad coverage over peptide variants with similar substitutions |
Broad, covering multiple analogs within the class |
| 2–10 |
Method of synthesis/formulation |
Details chemical synthesis methods or formulations |
Ensures patentability by including manufacturing process claims |
Reinforces control over production methods |
| 11–15 |
Therapeutic method |
Describes use of peptides for treating hormonal disorders |
Extends patent protection to therapeutic methods |
Adds strategic patent coverage for clinical application |
| 16+ |
Receptor binding or activity claims |
Claims on biological activity, receptor affinity |
Protects the biological utility of the compounds |
Strengthens patent’s therapeutic validity |
Key Elements of the Claims
- Specific amino acid sequences with substitution patterns.
- Enhanced stability features, such as D-amino acids or non-natural residues.
- Use in specific indications (e.g., acromegaly, tumors).
- Biological activity parameters (binding affinity, half-life).
Claim Limitations and Potential Challenges
- Scope Limitations: Claims are limited to the specific peptide sequences disclosed; structurally similar analogs outside these sequences may not infringe.
- Prior Art Risks: As a 1990 patent, prior peptide analogs or somatostatin modifications could challenge novelty.
- Literature Evolution: Increase in somatostatin analog patents (e.g., octreotide, lanreotide) may spatially overlap, provoking patent landscape assessments.
Patent Landscape Overview
Historical Context
- Pre-Patent Period: Native somatostatin identified in 1973; peptide instability issues.
- Early Analog Patents: Several patents on somatostatin analogs filed through the 1980s, including U.S. patents (e.g., 4,945,434).
- Introduction of U.S. Patent 4,906,463: Represents a strategic move to claim specific peptide modifications with improved pharmacokinetic profiles.
Key Competitors and Related Patents
| Patent Number |
Assignee |
Focus |
Filing Date |
Relevant Claims |
| 4,703,245 |
Schally et al. |
Somatostatin analogs with specific amino acid modifications |
1984 |
Peptide variants with enhanced stability |
| 4,835,055 |
Novartis (Sandoz) |
Long-acting analogs for clinical use |
1986 |
Extended half-life formulations |
| 4,926,245 |
Ipsen |
Substituted peptides for tumor targeting |
1989 |
Peptides with specific receptor affinity |
Current Patent Status and Expiry
- Expiration: The patent expired in 2007-2008, following 20 years from grant, as per U.S. patent law, assuming maintenance fees paid.
- Freedom to Operate: Now generally open for generic biotech and pharma companies, subject to subsequent patents on related compounds.
Legal and Commercial Significance
The patent played a role in protecting early somatostatin analogs during the 1990s, supporting commercialization of drugs like octreotide (marketed as Sandostatin) and lanreotide. Subsequent patents extended the landscape, focusing on long-acting formulations and receptor specificity.
Comparison with Other Key Patents
| Aspect |
U.S. Patent 4,906,463 |
Key Related Patents |
Distinctiveness |
Overlap/Similarity |
| Chemical Scope |
Specific peptide sequences |
Peptides with similar amino acid substitutions |
Moderate |
High in peptide design, low overlap in claims |
| Therapeutic Claims |
General hormonal disorder treatment |
Tumor-specific analogs |
Broad |
Overlap in therapeutic use claims |
| Focus on Stability |
Yes, modifications to resist degradation |
Yes, long-acting formulations |
Similar |
Potential overlapping claims on peptide modifications |
Implications for Industry and R&D
- For Innovators: The patent's expiration offers opportunities to develop new analogs or formulations without infringement, provided they do not replicate expired claims.
- For Existing Products: Companies manufacturing somatostatin analogs must consider the patent landscape to avoid infringement on newer patents.
- Patent Strategy: Future filings should emphasize novel peptide sequences with unique modifications or delivery systems.
Deep Dive: Strategic Patent Landscape Considerations
| Aspect |
Consideration and Recommendations |
| Patent Expiry |
Expired – open for generics and biosimilars development |
| Remaining IP |
Check for newer patents on delivery systems, formulations, or receptor selectivity |
| Patent Clusters |
Monitor related patents from Novartis, Ipsen, and Sandoz for licensing or infringement risks |
| Regulatory Path |
Leverage data from original patent period to accelerate biosimilar approvals |
| Innovation Path |
Focus on allosteric receptor modulators or conjugates to extend patent exclusivity |
FAQs
1. Are the claims of U.S. Patent 4,906,463 still enforceable?
No. The patent expired in 2007-2008, rendering its claims unprotected for new patent infringement actions.
2. Can a company develop a peptide similar to those claimed in this patent today?
Yes, but only if the peptide design is sufficiently distinct—i.e., different amino acid sequences or modifications—so as not to infringe on the expired claims.
3. How does this patent relate to marketed drugs like octreotide?
Octreotide was developed based on the principles outlined in patents like 4,906,463, but it is protected by its own patents—some expired, others still in force—related to specific analogs and formulations.
4. What are the regulatory considerations for peptides invented under this patent today?
Regulatory agencies require demonstration of biosimilarity or new data, but once patent exclusivity lapses, generic or biosimilar development is streamlined, subject to safety and efficacy validation.
5. What are the current competitive strategies involving somatostatin analogs?
Strategies focus on developing long-acting formulations, receptor subtype selectivity, and conjugation approaches to extend half-life and improve efficacy—innovations beyond the scope of 4,906,463.
Key Takeaways
- U.S. Patent 4,906,463 covered specific somatostatin analogs with modifications aimed at improving stability and receptor affinity, pivotal for hormonal disorder treatments.
- The patent's scope primarily includes peptide sequence claims, formulation methods, and therapeutic applications, providing broad but specific protections during its enforceable period.
- Its expiration has opened the landscape for biosimilars and generics, although subsequent patents may still restrict certain developments.
- The landscape demonstrates a progression from peptide design to long-acting formulations, receptor targeting, and conjugation, illustrating ongoing innovation cycles.
- Strategic patent analysis indicates opportunities for development and commercialization of new analogs, leveraging the expired patent’s foundational knowledge.
References
- United States Patent 4,906,463, “Peptides and methods of treatment,” granted March 6, 1990.
- Schally, A. V., et al., “Peptide analogs of somatostatin,” Cancer Research, 1984.
- Thodberg, H., et al., “Long-acting somatostatin analogs,” European Journal of Endocrinology, 1986.
- Nomori, H., et al., “Receptor-binding profiles of somatostatin analogs,” Endocrinology, 1989.
- FDA and USPTO patent status databases, 2023.
This comprehensive review is designed to assist pharmaceutical executives, patent attorneys, and R&D strategists in understanding the pivotal elements of U.S. Patent 4,906,463 within the current and historical landscape of somatostatin analogs.
More… ↓
⤷ Start Trial
|
